世界の糖尿病網膜症(DR)治療薬市場インサイト及び予測(~2026年)

【英語タイトル】Global Diabetic Retinopathy Drugs Market Size, Status and Forecast 2020-2026

QYResearchが出版した調査資料(QYR20NV11636)・商品コード:QYR20NV11636
・発行会社(調査会社):QYResearch
・発行日:2020年11月(※2024年版があります。お問い合わせください)
・ページ数:95
・レポート言語:英語
・レポート形式:PDF
・納品方法:Eメール(受注後3営業日)
・調査対象地域:グローバル
・産業分野:ヘルスケア
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD3,900 ⇒換算¥577,200見積依頼/購入/質問フォーム
Multi User(5名様閲覧用)USD5,850 ⇒換算¥865,800見積依頼/購入/質問フォーム
Enterprise License(同一法人内共有可)USD7,800 ⇒換算¥1,154,400見積依頼/購入/質問フォーム
販売価格オプションの説明
※お支払金額:換算金額(日本円)+消費税
※納期:即日〜2営業日(3日以上かかる場合は別途表記又はご連絡)
※お支払方法:納品日+5日以内に請求書を発行・郵送(請求書発行日より2ヶ月以内に銀行振込、振込先:三菱UFJ銀行/H&Iグローバルリサーチ株式会社、支払期限と方法は調整可能)
本調査レポートは糖尿病網膜症(DR)治療薬の世界市場について調査・分析した資料です。種類別(ルセンティス、オプチナ、イルビエン、ベタメタゾン、オズルデックス、その他)の市場規模、用途別(50〜60歳、60〜70歳、その他)の市場規模、地域別(北米、米国、カナダ、ヨーロッパ、ドイツ、フランス、イギリス、イタリア、ロシア、アジア、日本、中国、韓国、インド、オーストラリア、台湾、中南米、メキシコ、ブラジル、アルゼンチン、中東・アフリカ、トルコ、サウジアラビア、UAE等)の市場規模データ、主な企業情報と企業別市場シェア等が記載されています。
・調査範囲
・エグゼクティブサマリー
・企業別糖尿病網膜症(DR)治療薬の競争状況、市場シェア
・世界の糖尿病網膜症(DR)治療薬市場:種類別市場規模 2015年-2020年(ルセンティス、オプチナ、イルビエン、ベタメタゾン、オズルデックス、その他)
・世界の糖尿病網膜症(DR)治療薬市場:種類別市場規模予測 2021年-2026年(ルセンティス、オプチナ、イルビエン、ベタメタゾン、オズルデックス、その他)
・世界の糖尿病網膜症(DR)治療薬市場:用途別市場規模 2015年-2020年(50〜60歳、60〜70歳、その他)
・世界の糖尿病網膜症(DR)治療薬市場:用途別市場規模予測 2021年-2026年(50〜60歳、60〜70歳、その他)
・北米の糖尿病網膜症(DR)治療薬市場分析:米国、カナダ
・ヨーロッパの糖尿病網膜症(DR)治療薬市場分析:ドイツ、フランス、イギリス、イタリア、ロシア等
・アジアの糖尿病網膜症(DR)治療薬市場分析:日本、中国、韓国、インド、オーストラリア、台湾等
・中南米の糖尿病網膜症(DR)治療薬市場分析:メキシコ、ブラジル、アルゼンチン等
・中東・アフリカの糖尿病網膜症(DR)治療薬市場分析:トルコ、サウジアラビア、UAE等
・企業情報(企業概要、製品概要、販売量、企業動向)
- 掲載企業(変更可能性あり):Novartis、Bayer Healthcare、Roche、Neurotech Pharmaceuticals、Regeneron Pharmaceuticals、Allergan
・地域別市場規模予測(2021年-2026年):北米市場、ヨーロッパ市場、アジア市場、中南米市場、中東・アフリカ市場
・市場機会、課題、リスク、環境分析
・バリューチェーン、販売チャネル分析
・調査の結論
【レポートの概要】

Diabetic retinopathy is an ophthalmic disorder, in which blindness occurrs due to complications in diabetes.
The North American region is the most lucrative market, owing to large number of elderly population in the U.S. However, European and Asia-Pacific regions are considered as the most promising markets in the upcoming period.

Market Analysis and Insights: Global Diabetic Retinopathy Drugs Market
The global Diabetic Retinopathy Drugs market size is projected to reach US$ XX million by 2026, from US$ XX million in 2020, at a CAGR of XX%% during 2021-2026.

Global Diabetic Retinopathy Drugs Scope and Market Size
Diabetic Retinopathy Drugs market is segmented by Type, and by Application. Players, stakeholders, and other participants in the global Diabetic Retinopathy Drugs market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by Type and by Application in terms of revenue and forecast for the period 2015-2026.

The key players covered in this study
Novartis
Bayer Healthcare
Roche
Neurotech Pharmaceuticals
Regeneron Pharmaceuticals
Allergan

Market segment by Type, the product can be split into
Lucentis
Optina
Iluvien
Betamethazone
Ozurdex
Other
Market segment by Application, split into
50-60 Years Old
60-70 Years Old
Other

Market segment by Regions/Countries, this report covers
North America
Europe
China
Japan
Southeast Asia
India

【レポートの目次】

1 Report Overview
1.1 Study Scope
1.2 Key Market Segments
1.3 Players Covered: Ranking by Diabetic Retinopathy Drugs Revenue
1.4 Market by Type
1.4.1 Global Diabetic Retinopathy Drugs Market Size Growth Rate by Type: 2020 VS 2026
1.4.2 Lucentis
1.4.3 Optina
1.4.4 Iluvien
1.4.5 Betamethazone
1.4.6 Ozurdex
1.4.7 Other
1.5 Market by Application
1.5.1 Global Diabetic Retinopathy Drugs Market Share by Application: 2020 VS 2026
1.5.2 50-60 Years Old
1.5.3 60-70 Years Old
1.5.4 Other
1.6 Study Objectives
1.7 Years Considered

2 Global Growth Trends
2.1 Global Diabetic Retinopathy Drugs Market Perspective (2015-2026)
2.2 Global Diabetic Retinopathy Drugs Growth Trends by Regions
2.2.1 Diabetic Retinopathy Drugs Market Size by Regions: 2015 VS 2020 VS 2026
2.2.2 Diabetic Retinopathy Drugs Historic Market Share by Regions (2015-2020)
2.2.3 Diabetic Retinopathy Drugs Forecasted Market Size by Regions (2021-2026)
2.3 Industry Trends and Growth Strategy
2.3.1 Market Top Trends
2.3.2 Market Drivers
2.3.3 Market Challenges
2.3.4 Porter’s Five Forces Analysis
2.3.5 Diabetic Retinopathy Drugs Market Growth Strategy
2.3.6 Primary Interviews with Key Diabetic Retinopathy Drugs Players (Opinion Leaders)

3 Competition Landscape by Key Players
3.1 Global Top Diabetic Retinopathy Drugs Players by Market Size
3.1.1 Global Top Diabetic Retinopathy Drugs Players by Revenue (2015-2020)
3.1.2 Global Diabetic Retinopathy Drugs Revenue Market Share by Players (2015-2020)
3.1.3 Global Diabetic Retinopathy Drugs Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
3.2 Global Diabetic Retinopathy Drugs Market Concentration Ratio
3.2.1 Global Diabetic Retinopathy Drugs Market Concentration Ratio (CR5 and HHI)
3.2.2 Global Top 10 and Top 5 Companies by Diabetic Retinopathy Drugs Revenue in 2019
3.3 Diabetic Retinopathy Drugs Key Players Head office and Area Served
3.4 Key Players Diabetic Retinopathy Drugs Product Solution and Service
3.5 Date of Enter into Diabetic Retinopathy Drugs Market
3.6 Mergers & Acquisitions, Expansion Plans

4 Market Size by Type (2015-2026)
4.1 Global Diabetic Retinopathy Drugs Historic Market Size by Type (2015-2020)
4.2 Global Diabetic Retinopathy Drugs Forecasted Market Size by Type (2021-2026)

5 Market Size by Application (2015-2026)
5.1 Global Diabetic Retinopathy Drugs Market Size by Application (2015-2020)
5.2 Global Diabetic Retinopathy Drugs Forecasted Market Size by Application (2021-2026)

6 North America
6.1 North America Diabetic Retinopathy Drugs Market Size (2015-2020)
6.2 Diabetic Retinopathy Drugs Key Players in North America (2019-2020)
6.3 North America Diabetic Retinopathy Drugs Market Size by Type (2015-2020)
6.4 North America Diabetic Retinopathy Drugs Market Size by Application (2015-2020)

7 Europe
7.1 Europe Diabetic Retinopathy Drugs Market Size (2015-2020)
7.2 Diabetic Retinopathy Drugs Key Players in Europe (2019-2020)
7.3 Europe Diabetic Retinopathy Drugs Market Size by Type (2015-2020)
7.4 Europe Diabetic Retinopathy Drugs Market Size by Application (2015-2020)

8 China
8.1 China Diabetic Retinopathy Drugs Market Size (2015-2020)
8.2 Diabetic Retinopathy Drugs Key Players in China (2019-2020)
8.3 China Diabetic Retinopathy Drugs Market Size by Type (2015-2020)
8.4 China Diabetic Retinopathy Drugs Market Size by Application (2015-2020)

9 Japan
9.1 Japan Diabetic Retinopathy Drugs Market Size (2015-2020)
9.2 Diabetic Retinopathy Drugs Key Players in Japan (2019-2020)
9.3 Japan Diabetic Retinopathy Drugs Market Size by Type (2015-2020)
9.4 Japan Diabetic Retinopathy Drugs Market Size by Application (2015-2020)

10 Southeast Asia
10.1 Southeast Asia Diabetic Retinopathy Drugs Market Size (2015-2020)
10.2 Diabetic Retinopathy Drugs Key Players in Southeast Asia (2019-2020)
10.3 Southeast Asia Diabetic Retinopathy Drugs Market Size by Type (2015-2020)
10.4 Southeast Asia Diabetic Retinopathy Drugs Market Size by Application (2015-2020)

11 India
11.1 India Diabetic Retinopathy Drugs Market Size (2015-2020)
11.2 Diabetic Retinopathy Drugs Key Players in India (2019-2020)
11.3 India Diabetic Retinopathy Drugs Market Size by Type (2015-2020)
11.4 India Diabetic Retinopathy Drugs Market Size by Application (2015-2020)

12 Central & South America
12.1 Central & South America Diabetic Retinopathy Drugs Market Size (2015-2020)
12.2 Diabetic Retinopathy Drugs Key Players in Central & South America (2019-2020)
12.3 Central & South America Diabetic Retinopathy Drugs Market Size by Type (2015-2020)
12.4 Central & South America Diabetic Retinopathy Drugs Market Size by Application (2015-2020)

13 Key Players Profiles
13.1 Novartis
13.1.1 Novartis Company Details
13.1.2 Novartis Business Overview
13.1.3 Novartis Diabetic Retinopathy Drugs Introduction
13.1.4 Novartis Revenue in Diabetic Retinopathy Drugs Business (2015-2020))
13.1.5 Novartis Recent Development
13.2 Bayer Healthcare
13.2.1 Bayer Healthcare Company Details
13.2.2 Bayer Healthcare Business Overview
13.2.3 Bayer Healthcare Diabetic Retinopathy Drugs Introduction
13.2.4 Bayer Healthcare Revenue in Diabetic Retinopathy Drugs Business (2015-2020)
13.2.5 Bayer Healthcare Recent Development
13.3 Roche
13.3.1 Roche Company Details
13.3.2 Roche Business Overview
13.3.3 Roche Diabetic Retinopathy Drugs Introduction
13.3.4 Roche Revenue in Diabetic Retinopathy Drugs Business (2015-2020)
13.3.5 Roche Recent Development
13.4 Neurotech Pharmaceuticals
13.4.1 Neurotech Pharmaceuticals Company Details
13.4.2 Neurotech Pharmaceuticals Business Overview
13.4.3 Neurotech Pharmaceuticals Diabetic Retinopathy Drugs Introduction
13.4.4 Neurotech Pharmaceuticals Revenue in Diabetic Retinopathy Drugs Business (2015-2020)
13.4.5 Neurotech Pharmaceuticals Recent Development
13.5 Regeneron Pharmaceuticals
13.5.1 Regeneron Pharmaceuticals Company Details
13.5.2 Regeneron Pharmaceuticals Business Overview
13.5.3 Regeneron Pharmaceuticals Diabetic Retinopathy Drugs Introduction
13.5.4 Regeneron Pharmaceuticals Revenue in Diabetic Retinopathy Drugs Business (2015-2020)
13.5.5 Regeneron Pharmaceuticals Recent Development
13.6 Allergan
13.6.1 Allergan Company Details
13.6.2 Allergan Business Overview
13.6.3 Allergan Diabetic Retinopathy Drugs Introduction
13.6.4 Allergan Revenue in Diabetic Retinopathy Drugs Business (2015-2020)
13.6.5 Allergan Recent Development

14 Analyst’s Viewpoints/Conclusions

15 Appendix
15.1 Research Methodology
15.1.1 Methodology/Research Approach
15.1.2 Data Source
15.2 Disclaimer
15.3 Author Details

List of Tables
Table 1. Diabetic Retinopathy Drugs Key Market Segments
Table 2. Key Players Covered: Ranking by Diabetic Retinopathy Drugs Revenue
Table 3. Ranking of Global Top Diabetic Retinopathy Drugs Manufacturers by Revenue (US$ Million) in 2019
Table 4. Global Diabetic Retinopathy Drugs Market Size Growth Rate by Type (US$ Million): 2020 VS 2026
Table 5. Key Players of Lucentis
Table 6. Key Players of Optina
Table 7. Key Players of Iluvien
Table 8. Key Players of Betamethazone
Table 9. Key Players of Ozurdex
Table 10. Key Players of Other
Table 11. Global Diabetic Retinopathy Drugs Market Size Growth by Application (US$ Million): 2020 VS 2026
Table 12. Global Diabetic Retinopathy Drugs Market Size by Regions (US$ Million): 2020 VS 2026
Table 13. Global Diabetic Retinopathy Drugs Market Size by Regions (2015-2020) (US$ Million)
Table 14. Global Diabetic Retinopathy Drugs Market Share by Regions (2015-2020)
Table 15. Global Diabetic Retinopathy Drugs Forecasted Market Size by Regions (2021-2026) (US$ Million)
Table 16. Global Diabetic Retinopathy Drugs Market Share by Regions (2021-2026)
Table 17. Market Top Trends
Table 18. Key Drivers: Impact Analysis
Table 19. Key Challenges
Table 20. Diabetic Retinopathy Drugs Market Growth Strategy
Table 21. Main Points Interviewed from Key Diabetic Retinopathy Drugs Players
Table 22. Global Diabetic Retinopathy Drugs Revenue by Players (2015-2020) (Million US$)
Table 23. Global Diabetic Retinopathy Drugs Market Share by Players (2015-2020)
Table 24. Global Top Diabetic Retinopathy Drugs Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Diabetic Retinopathy Drugs as of 2019)
Table 25. Global Diabetic Retinopathy Drugs by Players Market Concentration Ratio (CR5 and HHI)
Table 26. Key Players Headquarters and Area Served
Table 27. Key Players Diabetic Retinopathy Drugs Product Solution and Service
Table 28. Date of Enter into Diabetic Retinopathy Drugs Market
Table 29. Mergers & Acquisitions, Expansion Plans
Table 30. Global Diabetic Retinopathy Drugs Market Size by Type (2015-2020) (Million US$)
Table 31. Global Diabetic Retinopathy Drugs Market Size Share by Type (2015-2020)
Table 32. Global Diabetic Retinopathy Drugs Revenue Market Share by Type (2021-2026)
Table 33. Global Diabetic Retinopathy Drugs Market Size Share by Application (2015-2020)
Table 34. Global Diabetic Retinopathy Drugs Market Size by Application (2015-2020) (Million US$)
Table 35. Global Diabetic Retinopathy Drugs Market Size Share by Application (2021-2026)
Table 36. North America Key Players Diabetic Retinopathy Drugs Revenue (2019-2020) (Million US$)
Table 37. North America Key Players Diabetic Retinopathy Drugs Market Share (2019-2020)
Table 38. North America Diabetic Retinopathy Drugs Market Size by Type (2015-2020) (Million US$)
Table 39. North America Diabetic Retinopathy Drugs Market Share by Type (2015-2020)
Table 40. North America Diabetic Retinopathy Drugs Market Size by Application (2015-2020) (Million US$)
Table 41. North America Diabetic Retinopathy Drugs Market Share by Application (2015-2020)
Table 42. Europe Key Players Diabetic Retinopathy Drugs Revenue (2019-2020) (Million US$)
Table 43. Europe Key Players Diabetic Retinopathy Drugs Market Share (2019-2020)
Table 44. Europe Diabetic Retinopathy Drugs Market Size by Type (2015-2020) (Million US$)
Table 45. Europe Diabetic Retinopathy Drugs Market Share by Type (2015-2020)
Table 46. Europe Diabetic Retinopathy Drugs Market Size by Application (2015-2020) (Million US$)
Table 47. Europe Diabetic Retinopathy Drugs Market Share by Application (2015-2020)
Table 48. China Key Players Diabetic Retinopathy Drugs Revenue (2019-2020) (Million US$)
Table 49. China Key Players Diabetic Retinopathy Drugs Market Share (2019-2020)
Table 50. China Diabetic Retinopathy Drugs Market Size by Type (2015-2020) (Million US$)
Table 51. China Diabetic Retinopathy Drugs Market Share by Type (2015-2020)
Table 52. China Diabetic Retinopathy Drugs Market Size by Application (2015-2020) (Million US$)
Table 53. China Diabetic Retinopathy Drugs Market Share by Application (2015-2020)
Table 54. Japan Key Players Diabetic Retinopathy Drugs Revenue (2019-2020) (Million US$)
Table 55. Japan Key Players Diabetic Retinopathy Drugs Market Share (2019-2020)
Table 56. Japan Diabetic Retinopathy Drugs Market Size by Type (2015-2020) (Million US$)
Table 57. Japan Diabetic Retinopathy Drugs Market Share by Type (2015-2020)
Table 58. Japan Diabetic Retinopathy Drugs Market Size by Application (2015-2020) (Million US$)
Table 59. Japan Diabetic Retinopathy Drugs Market Share by Application (2015-2020)
Table 60. Southeast Asia Key Players Diabetic Retinopathy Drugs Revenue (2019-2020) (Million US$)
Table 61. Southeast Asia Key Players Diabetic Retinopathy Drugs Market Share (2019-2020)
Table 62. Southeast Asia Diabetic Retinopathy Drugs Market Size by Type (2015-2020) (Million US$)
Table 63. Southeast Asia Diabetic Retinopathy Drugs Market Share by Type (2015-2020)
Table 64. Southeast Asia Diabetic Retinopathy Drugs Market Size by Application (2015-2020) (Million US$)
Table 65. Southeast Asia Diabetic Retinopathy Drugs Market Share by Application (2015-2020)
Table 66. India Key Players Diabetic Retinopathy Drugs Revenue (2019-2020) (Million US$)
Table 67. India Key Players Diabetic Retinopathy Drugs Market Share (2019-2020)
Table 68. India Diabetic Retinopathy Drugs Market Size by Type (2015-2020) (Million US$)
Table 69. India Diabetic Retinopathy Drugs Market Share by Type (2015-2020)
Table 70. India Diabetic Retinopathy Drugs Market Size by Application (2015-2020) (Million US$)
Table 71. India Diabetic Retinopathy Drugs Market Share by Application (2015-2020)
Table 72. Central & South America Key Players Diabetic Retinopathy Drugs Revenue (2019-2020) (Million US$)
Table 73. Central & South America Key Players Diabetic Retinopathy Drugs Market Share (2019-2020)
Table 74. Central & South America Diabetic Retinopathy Drugs Market Size by Type (2015-2020) (Million US$)
Table 75. Central & South America Diabetic Retinopathy Drugs Market Share by Type (2015-2020)
Table 76. Central & South America Diabetic Retinopathy Drugs Market Size by Application (2015-2020) (Million US$)
Table 77. Central & South America Diabetic Retinopathy Drugs Market Share by Application (2015-2020)
Table 78. Novartis Company Details
Table 79. Novartis Business Overview
Table 80. Novartis Product
Table 81. Novartis Revenue in Diabetic Retinopathy Drugs Business (2015-2020) (Million US$)
Table 82. Novartis Recent Development
Table 83. Bayer Healthcare Company Details
Table 84. Bayer Healthcare Business Overview
Table 85. Bayer Healthcare Product
Table 86. Bayer Healthcare Revenue in Diabetic Retinopathy Drugs Business (2015-2020) (Million US$)
Table 87. Bayer Healthcare Recent Development
Table 88. Roche Company Details
Table 89. Roche Business Overview
Table 90. Roche Product
Table 91. Roche Revenue in Diabetic Retinopathy Drugs Business (2015-2020) (Million US$)
Table 92. Roche Recent Development
Table 93. Neurotech Pharmaceuticals Company Details
Table 94. Neurotech Pharmaceuticals Business Overview
Table 95. Neurotech Pharmaceuticals Product
Table 96. Neurotech Pharmaceuticals Revenue in Diabetic Retinopathy Drugs Business (2015-2020) (Million US$)
Table 97. Neurotech Pharmaceuticals Recent Development
Table 98. Regeneron Pharmaceuticals Company Details
Table 99. Regeneron Pharmaceuticals Business Overview
Table 100. Regeneron Pharmaceuticals Product
Table 101. Regeneron Pharmaceuticals Revenue in Diabetic Retinopathy Drugs Business (2015-2020) (Million US$)
Table 102. Regeneron Pharmaceuticals Recent Development
Table 103. Allergan Company Details
Table 104. Allergan Business Overview
Table 105. Allergan Product
Table 106. Allergan Revenue in Diabetic Retinopathy Drugs Business (2015-2020) (Million US$)
Table 107. Allergan Recent Development
Table 108. Research Programs/Design for This Report
Table 109. Key Data Information from Secondary Sources
Table 110. Key Data Information from Primary Sources
List of Figures
Figure 1. Global Diabetic Retinopathy Drugs Market Share by Type: 2020 VS 2026
Figure 2. Lucentis Features
Figure 3. Optina Features
Figure 4. Iluvien Features
Figure 5. Betamethazone Features
Figure 6. Ozurdex Features
Figure 7. Other Features
Figure 8. Global Diabetic Retinopathy Drugs Market Share by Application: 2020 VS 2026
Figure 9. 50-60 Years Old Case Studies
Figure 10. 60-70 Years Old Case Studies
Figure 11. Other Case Studies
Figure 12. Diabetic Retinopathy Drugs Report Years Considered
Figure 13. Global Diabetic Retinopathy Drugs Market Size YoY Growth 2015-2026 (US$ Million)
Figure 14. Global Diabetic Retinopathy Drugs Market Share by Regions: 2020 VS 2026
Figure 15. Global Diabetic Retinopathy Drugs Market Share by Regions (2021-2026)
Figure 16. Porter's Five Forces Analysis
Figure 17. Global Diabetic Retinopathy Drugs Market Share by Players in 2019
Figure 18. Global Top Diabetic Retinopathy Drugs Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Diabetic Retinopathy Drugs as of 2019
Figure 19. The Top 10 and 5 Players Market Share by Diabetic Retinopathy Drugs Revenue in 2019
Figure 20. North America Diabetic Retinopathy Drugs Market Size YoY Growth (2015-2020) (Million US$)
Figure 21. Europe Diabetic Retinopathy Drugs Market Size YoY Growth (2015-2020) (Million US$)
Figure 22. China Diabetic Retinopathy Drugs Market Size YoY Growth (2015-2020) (Million US$)
Figure 23. Japan Diabetic Retinopathy Drugs Market Size YoY Growth (2015-2020) (Million US$)
Figure 24. Southeast Asia Diabetic Retinopathy Drugs Market Size YoY Growth (2015-2020) (Million US$)
Figure 25. India Diabetic Retinopathy Drugs Market Size YoY Growth (2015-2020) (Million US$)
Figure 26. Central & South America Diabetic Retinopathy Drugs Market Size YoY Growth (2015-2020) (Million US$)
Figure 27. Bottom-up and Top-down Approaches for This Report
Figure 28. Data Triangulation
Figure 29. Key Executives Interviewed


【掲載企業】

Novartis、Bayer Healthcare、Roche、Neurotech Pharmaceuticals、Regeneron Pharmaceuticals、Allergan

★調査レポート[世界の糖尿病網膜症(DR)治療薬市場インサイト及び予測(~2026年)] (コード:QYR20NV11636)販売に関する免責事項を必ずご確認ください。
★調査レポート[世界の糖尿病網膜症(DR)治療薬市場インサイト及び予測(~2026年)]についてメールでお問い合わせ


◆H&Iグローバルリサーチのお客様(例)◆